北京三有利和泽生物科技

Beijing Sanyouli Heze Biotechnology is a clinical-stage biopharmaceutical company headquartered in Beijing, China, specializing in the development of regenerative medicine and mesenchymal stem cell (MSC) therapies. The company was founded by Academician Wu Zuze, a pioneer in China's hematopoietic stem cell research, and focuses on utilizing human umbilical cord-derived MSCs (hUC-MSCs) to treat complex autoimmune and inflammatory conditions. Its robust clinical pipeline includes advanced programs for chronic graft-versus-host disease, systemic lupus erythematosus, and knee osteoarthritis, several of which are currently in Phase 2 trials. Sanyouli Heze operates integrated R&D and GMP-compliant manufacturing facilities to ensure the standardized production of high-quality cell therapy products. The company aims to bridge the gap between basic stem cell research and clinical application to provide innovative treatments for patients with limited options.